Analysts Are Bullish on These Healthcare Stocks: Candel Therapeutics (CADL), Gain Therapeutics (GANX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Candel Therapeutics (CADL – Research Report) and Gain Therapeutics (GANX – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Candel Therapeutics (CADL)

H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Candel Therapeutics today and set a price target of $23.00. The company’s shares closed last Tuesday at $5.78.

According to TipRanks.com, Maldonado is a 5-star analyst with an average return of 23.9% and a 58.6% success rate. Maldonado covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Zentalis Pharmaceuticals, and Monopar Therapeutics Inc. ;'>

Candel Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20.00.

See today’s best-performing stocks on TipRanks >>

Gain Therapeutics (GANX)

BTIG analyst Thomas Shrader maintained a Buy rating on Gain Therapeutics yesterday and set a price target of $9.00. The company’s shares closed last Tuesday at $2.04.

According to TipRanks.com, Shrader is a 4-star analyst with an average return of 5.9% and a 41.4% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Acumen Pharmaceuticals, and ProMIS Neurosciences. ;'>

Gain Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $7.60, implying a 297.9% upside from current levels. In a report issued on October 7, Maxim Group also maintained a Buy rating on the stock with a $7.00 price target.

Read More on CADL:

Disclaimer & DisclosureReport an Issue

• Candel Therapeutics Secures $130M Loan for Trials
• Candel Therapeutics enters into $130M term loan facility
• Candel Therapeutics announces interim data from phase 1b CAN-3110 trial
• Trinity Capital provides $130M in growth capital to Candel Therapeutics
• Promising Investment: Candel Therapeutics’ CAN-2409 Shows Efficacy in Prostate Cancer with Potential for Broader Applications